Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report (2026)

Peer-Reviewed Study · Grace E. Powderly, K. Hassevoort, M. Loy, J. Balonier, C. Sievers · May 15, 2026

Grace E. Powderly et al., 2026-05-15: Case report of severe hepatocellular liver injury (ALT 1764 U/L) in a 65-year-old man with prostate cancer taking veterinary fenbendazole and ivermectin daily for three months, scored 'highly probable' on RUCAM and resolving after cessation.

We report a rare case of severe drug-induced liver injury (DILI) in a 65-year-old male with prostate cancer resulting from the concurrent ingestion of veterinary-grade fenbendazole and ivermectin.

Grace E. Powderly et al., 2026-05-15: Case report of severe hepatocellular liver injury (ALT 1764 U/L) in a 65-year-old man with prostate cancer taking veterinary fenbendazole and ivermectin daily for three months, scored 'highly probable' on RUCAM and resolving after cessation. C3. Study type: single case report, n=1, United States (A.T. Still University; Western Reserve Hospital, Ohio). Dose as reported: 'one squirt' daily of veterinary product, estimated 0.18 mg/kg ivermectin and 0.98 mg/kg fenbendazole, alternating agents daily for 3 months. Other treatment: none of the anticancer kind; the intervention was self-directed. Outcome: ALT 1764 U/L, AST 1132 U/L, bilirubin 12.9 mg/dL, R-value 37.50, RUCAM 9 ('highly probable'); transaminases fell 58% within 9 days and normalised within 6 weeks of stopping. Funding: 'no financial support was received from any organization'. Disclosures: no financial relationships declared. Product/maker: veterinary-grade product, maker not named. Comparator: none (dechallenge only). Study type: case report.